MedWatch

Logistics and comparisons will bring growth down for Ambu, analyst says

Senior analyst at Sydbank Søren Løntoft Hansen has subdued expectations for the first quarter of medtech company Ambu.

Photo: Ambu / PR

The first quarter for the skewed 2021/2022 financial year will be marked by a difficult basis of comparison and continued logistical challenges, both of which will put a damper on the report, says Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank, prior to the report’s release on February 8.

”Ambu’s first quarter will be characterized by a difficult basis of comparison within its Visualization business. Add to this continued logistic challenges in Ambu’s core business, which will, in our assessment, dampen growth in the quarter. We estimate a total organic growth of 1 percent, while a positive currency effect will lift up revenue,” the analyst writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs